Hansa Biopharma Ab · OMXSTO:HNSA
Hansa Biopharma Ab — Q2 2022 Earnings Presentation
15 slides from Hansa Biopharma Ab's earnings presentation, Jul 19, 2022
Slide 1: Conference Call Presentation Interim Report Q2 2022
Conference Call Presentation Interim Report Q2 2022 Lund, July 19, 2022
Slide 2: Forward-looking statements
Forward-looking statements This presentation may contain certain forward-looking statements and forecasts based on our current expectations and beliefs regarding future events and are subject to significant uncertainties and risks since they relate to events and depend on circumstances that will occ
Slide 3: Highlights for the second quarter of 2022
Continued solid sales in Q2; Positive recommendation by NICE; Patient enrollment completed in AMR; Peter Nicklin appointed as new Chairman of the Board Highlights for the second quarter of 2022 ü Launch activities and market access efforts in EU progressing as planned - Continued solid sales, with S
Slide 4: Recommendation by NICE is an important step forward for commercialization
Recommendation by NICE is an important step forward for our commercialization efforts and for patients in England, Wales & Northern Ireland NICE considers Idefirix® to be a clinically- and cost-effective treatment; Market access has now been secured in 7 European countries and procedures are ongoing
Slide 5: First patient treated in post-authorization efficacy study (PAES) of Idefirix
First patient treated in post-authorization efficacy study (PAES) of Idefirix® (imlifidase) in highly sensitized kidney transplant patients The study will provide further important insights regarding Idefirix® desensitization treatment of highly sensitized kidney transplant patients An open-label Ph
Slide 6: Continuous progress in our ongoing clinical Programs
Continuous progress in our ongoing clinical Programs Enrollment status Enrollment status July 19, 2022 July 19, 2022 Antibody Mediated Rejection Phase 2 study Anti-GBM Phase 3 study • 30/30 patients enrolled in the AMR phase 2 study • FDA has accepted Hansa’s Investigational New Drug • Completion of
Slide 7: Broad clinical pipeline in transplantation and auto-immune diseases
Broad clinical pipeline in transplantation and auto-immune diseases Candidate/ Research/ Marketing Program Indication Preclinical Phase 1 Phase 2 Phase 3 Authorization Marketed Next Anticipated Milestone EU: Additional agreements EU: Kidney transplantation in highly sensitized patients 1,2 around re
Slide 8: Continued solid sales in Q2 with product sales of SEK 19.5m
Continued solid sales in Q2 with product sales of SEK 19.5m; Total H1-2022 revenue SEK 56.7m Revenue (Q/Q) Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 30,3 26,4 Product sales 15,4 24.2 19.5 SEKm 9.0 4,5 4,9 5.3 6.2 Revenue recognition Sarepta 3.6 4.4 5.2 0.9 0.6 1.1 0.8 0.8 Axis-Shield Revenue (HY/HY) H1'20 H1'21
Slide 9: Continued investments in commercialization and our pipeline
Continued investments in commercialization and our pipeline SG&A expenses (Q/Q) R&D expenses (Q/Q) Net loss (Q/Q) Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 -81 -83 -80 -90 -103 -55 -61 SEKm SEKm SEKm -68 -71 -133 -138 -148 -163 -170 -93 SG&A expenses (
Slide 10: Cash runway extended through 2024 with NovaQuest financing
With recent financing transaction secured with NovaQuest; Hansa’s cash runway has extended through 2024 Operating cash flow (Q/Q) Cash & short-term investments (Q/Q) Cash position post recent financing transaction Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 ~1,300 (USD 130m) SEKm -113 -132 -116 -130 -136 1,139 1,
Slide 11: $70 million non-dilutive financing transaction to support platform development
$70 million non-dilutive financing transaction to support the continued development of Hansa’s antibody-cleaving enzyme technology platform Transaction extends cash runway through 2024 and helps bolster the ability to invest in the continued development of our unique antibody-cleaving enzyme technol
Slide 12: Upcoming milestones
Upcoming milestones Milestones subject to potential COVID-19 impact Anti-GBM Kidney transplantation GBS Kidney Initiation of U.S. complete Phase 2 complete GBS Phase 2 transplantation Phase 3 study enrollment enrollment first data read out U.S. BLA submission (2022) (H2 2022) (H2 2022) (H1 2023) (H1
Slide 13: Q&A
Q&A … at Hansa Biopharma we envision a world Visit our web site www.hansabiopharma.com where all patients with rare immunologic diseases can lead long and healthy lives… 13
Slide 14: Corporate Contacts
Corporate Contacts Visit our web site Investor Relations and www.hansabiopharma.com Corporate Communications Calendar and events Aug 9, 2022 BTIG Biotechnology Conference 2022, New York Klaus Sindahl Aug 10, 2022 Kempen US non-deal road show, New York Aug 11, 2022 Canaccord Annual Growth Conference,
Slide 15: HANSAT
MZ HANSAT BIOPHARMA